115010-11-2

Usage

Uses

Used in Pharmaceutical Industry:
2,3-Dihydro-1-benzofuran-5-sulfonyl chloride is used as a key intermediate in the synthesis of various pharmaceuticals. Its reactivity with nucleophiles allows for the formation of sulfonamides and sulfonates, which are essential functional groups in the development of new drugs.
Used in Agrochemical Industry:
2,3-Dihydro-1-benzofuran-5-sulfonyl chloride is also utilized in the preparation of agrochemicals, contributing to the development of new pesticides and other agricultural chemicals that can improve crop protection and yield.
Used in Dye and Pigment Production:
2,3-Dihydro-1-benzofuran-5-sulfonyl chloride is used as a building block in the production of dyes and pigments, enabling the creation of a diverse range of colorants for various applications, including textiles, plastics, and printing inks.
Used in Polymer Industry:
2,3-Dihydro-1-benzofuran-5-sulfonyl chloride is employed in the synthesis of polymers, where its unique chemical properties can be leveraged to develop new materials with specific characteristics, such as improved strength, flexibility, or chemical resistance.

InChI:InChI=1/C8H7ClO3S/c9-13(10,11)7-1-2-8-6(5-7)3-4-12-8/h1-2,5H,3-4H2

Upstream product

• 496-16-2 2.3-dihydrobenzofuran 
• 107-06-2 1,2-dichloro-ethane 
• 7790-94-5 chlorosulfonic acid 

Downstream Products

• 856678-57-4 7-iodo-2,3-dihydro-benzofuran-5-sulfonylchloride 
• 869885-60-9 1-benzofuran-5-sulfonyl chloride 
• 1035342-24-5 N-[(2S)-1-[6-chloro-1-(4-fluorophenyl)indazol-5-yl]oxypropan-2-yl]-2,3-dihydrobenzofuran-5-sulfonamide 
• 368426-43-1 [4-({2-[3-(2,3-dihydro-benzofuran-5-sulfonylamino)-2-oxo-azepan-1-yl]-acetylamino}-methyl)-cyclohexyl]-carbamic acid tert-butyl ester 
• 368426-31-7 2-[3-(2,3-dihydro-benzofuran-5-sulfonylamino)-2-oxo-azepan-1-yl]-N-[4-(N-hydroxycarbamimidoyl)-benzyl]-acetamide 
• 368426-10-2 [(S)-3-(2,3-Dihydro-benzofuran-5-sulfonylamino)-2-oxo-azepan-1-yl]-acetic acid benzyl ester 
• 183554-05-4 2S-[[(pyrrolidin-1-yl)acetyl]amino]-N-[2R-hydroxy-3-[[(2,3-dihydrobenzofuran-5-yl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-3,3-dimethyl-butanamide 
• 368426-47-5 [3-(2,3-dihydro-benzofuran-5-sulfonylamino)-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl]-acetic acid benzyl ester 

Relevant academic research and scientific papers

Piperazine adenosine monophosphate activated protein kinase (AMPK) agonist and medical application thereof

The invention discloses a piperazine compound with AMPK agonist activity, and a preparation method and medical application of the piperazine compound. The piperazine compound is a compound shown as aformula (I) (please see the specifications for the formula), and a pharmaceutically acceptable salt or ester or a prodrug or N-oxide or solvate thereof. The compound can be used for preparing drugs for preventing or treating AMPK-mediated diseases.

BENZOFURAN DERIVED HIV PROTEASE INHIBITORS

Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

NEW BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS .

The present invention relates to compounds of the general Formula (I), wherein R1, R2 and R3 are as defined in the description; to pharmaceutical compositions comprising these compounds; and to the use of the compounds for

Resistance-repellent retroviral protease inhibitors

Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

NOVEL BENZOFURAN DERIVATIVES, WHICH CAN BE USED IN PROPHYLAXIS OR TREATMENT OF 5-HT6 RECEPTOR-RELATED DISORDER

The present invention relates to compounds of formula (I): wherein P, R3, W1, and W2 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.

Non-covalent thrombin inhibitors

The present invention provides compounds which have a pyrazinone or pyridinone ring at P3 and which feature a six member heterocyclic ring having two ring nitrogen atoms and the remainder of the ring atoms carbon atoms at P1. These compounds have biologic

Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors

Selected bis-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.

Sulfonamide inhibitors of aspartyl protease

The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

HETEROCYCLECARBONYL AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS

Selected heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.